| Project/Area Number |
20590844
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
TAKAGI Gen 日本医科大学, 医学部, 助教 (00301565)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAMOTO Masaaki 日本医科大学, 医学部, 准教授 (50229895)
YASUTAKE Masahiro 日本医科大学, 医学部, 准教授 (70281433)
MIZUNO Kyoichi 日本医科大学, 大学院・医学研究科, 教授 (00267121)
|
|---|
| Project Period (FY) |
2008 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Keywords | 移植・再生医療 / 膠原病 / ドラッグデリバリー / 血管炎 / 血管新生 |
|---|
| Research Abstract |
To date, clinical studies on promoting therapeutic angiogenesis in ischemic tissues have focused exclusively on the use of cell therapy or angiogenic growth factors. In fact, autologous mononuclear cell is reported that potential effective approach for peripheral artery disease and the mechanism is based on the production of variable cytokines from mononuclear cells. An optimal delivery strategy has not been established yet. To establish therapeutic angiogenesis strategies applying for intractable vasculitis, we investigated a therapeutic angiogenesis that could safely cure intractable ulcers, utilizing basic fibroblast growth factor application with a drug-delivery system(DDS). 1^<st> year, we reported ideal methodological approach to evaluate clinical angiogenesis. 2^<nd> to 3^<rd> year, the clinical effect for Churg-Strauss syndrome and SLE were reported. At final year, the effect of this therapy was compared with bone marrow mononuclear cells implantation for atherosclerosis obliterans and Buerger's disease. These widely effective clinical effects for variable intractable vasculitis were published to the book "Vasculitis", with attract attention from worldwide.
|
